A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
Recruiting · Phase 3 · NCT07022483
Conditions: Endometrial Cancer
At a glance
- Research payments reported, 2025
- $47,300
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 710
About the trial
- Sponsor
- Daiichi Sankyo (with AstraZeneca)
- Tested
- Trastuzumab Deruxtecan (drug), Chemotherapy (drug)
- Dates
- Started 2025-09-30; completion 2032-03-23
- Results posted
- Not yet
This study is designed to assess efficacy and safety of T-DXd adjuvant therapy, with or without radiotherapy, post-surgery in anticancer treatment naïve (including neoadjuvant therapy) endometrial cancer with various HER2 expression levels.
From ClinicalTrials.gov, last updated 2026-10-27. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $47,300 in research payments for this study in 2025 (2 payments).
Products named: Enhertu
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Brian M. Slomovitz, M.D. Gynecologic Oncology · Fort Lauderdale, FL
- Destin R. Black, MD Gynecologic Oncology · Shreveport, LA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Mount Sinai Medical Center of Florida, Inc, FL $29,375
- Trials365, Llc $17,925
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.